Intravenous treatment of experimental Parkinson's disease in the mouse with an IgG-GDNF fusion protein that penetrates the blood-brain barrier

Brain Research

Volumn 1352, Issue , 2010, Pages 208-213

  Fu, Ailing ^a   Zhou, Qing Hui ^a   Hui, Eric Ka Wai ^b   Lu, Jeff Zhiqiang ^b   Boado, Ruben J ^a,b   Pardridge, William M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ArmaGen Technologies Inc   (United States)

Author keywords

Blood brain barrier; GDNF; Monoclonal antibody; Parkinson's disease

Indexed keywords

AMPHETAMINE; APOMORPHINE; CHIMERIC TRANSFERRIN RECEPTOR MONOCLONAL ANTIBODY PLUS GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; HYBRID PROTEIN; IMMUNOGLOBULIN G; TRANSFERRIN RECEPTOR; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; ENZYME ACTIVITY; FORELIMB; FRONTAL CORTEX; GENE EXPRESSION; HEAVY CHAIN; IN VIVO STUDY; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN ENGINEERING; PROTEIN TRANSPORT; ROTATION; SIGNAL TRANSDUCTION;

ANIMALS; BLOOD-BRAIN BARRIER; CORPUS STRIATUM; FORELIMB; FUNCTIONAL LATERALITY; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; IMMUNOGLOBULIN G; MICE; MOTOR ACTIVITY; PARKINSONIAN DISORDERS; RECOMBINANT FUSION PROTEINS; ROTATION; SUBSTANTIA NIGRA; VIBRISSAE;

EQUIDAE; MUS;

EID: 77956178352     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2010.06.059     Document Type: Article

References (26)

1. K.K. Anstrom, T. Schallert, M.T. Woodlee, A. Shattuck, and D.C. Roberts Repetitive vibrissae-elicited forelimb placing before and immediately after unilateral 6-hydroxydopamine improves outcome in a model of Parkinson's disease Behav. Brain Res. 179 2007 183 191
2. A. Arvidsson, Z. Kokaia, M.S. Airaksinen, M. Saarma, and O. Lindvall Stroke induces widespread changes of gene expression for glial cell line-derived neurotrophic factor family receptors in the adult rat brain Neuroscience 106 2001 27 41
3. R.J. Boado, and W.M. Pardridge Comparison of blood-brain barrier transport of glial-derived neurotrophic factor (GDNF) and an IgG-GDNF fusion protein in the rhesus monkey Drug Metab. Dispos. 37 2009 2299 2304
4. R.J. Boado, Y. Zhang, Y. Wang, and W.M. Pardridge GDNF fusion protein for targeted-drug delivery across the human blood-brain barrier Biotechnol. Bioeng. 100 2008 387 396
5. R.J. Boado, Y. Zhang, Y. Wang, and W.M. Pardridge Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood-brain barrier delivery in the mouse Biotechnol. Bioeng. 102 2009 1251 1258
6. Q. Cheng, V. Di Liberto, G. Caniglia, and G. Mudo Time-course of GDNF and its receptor expression after brain injury in the rat Neurosci. Lett. 439 2008 24 29
7. I. Date, M. Aoi, S. Tomita, F. Collins, and T. Ohmoto GDNF administration induces recovery of the nigrostriatal dopaminergic system both in young and aged parkinsonian mice NeuroReport 9 1998 2365 2369
8. A.S. De Groot, L. Moise, J.A. McMurry, E. Wambre, L. Van Overtvelt, P. Moingeon, D.W. Scott, and W. Martin Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes" Blood 112 2008 3303 3311
9. G.P. Dietz, P.C. Valbuena, B. Dietz, K. Meuer, P. Mueller, J.H. Weishaupt, and M. Bahr Application of a blood-brain-barrier-penetrating form of GDNF in a mouse model for Parkinson's disease Brain Res. 1082 2006 61 66
10. S. Eketjall, M. Fainzilber, J. Murray-Rust, and C.F. Ibanez Distinct structural elements in GDNF mediate binding to GFRalpha1 and activation of the GFRalpha1-c-Ret receptor complex EMBO J. 18 1999 5901 5910
11. B.J. Hoffer, A. Hoffman, K. Bowenkamp, P. Huettl, J. Hudson, D. Martin, L.F. Lin, and G.A. Gerhardt Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo Neurosci. Lett. 182 1994 107 111
12. A.J. Kastin, V. Akerstrom, and W. Pan Glial cell line-derived neurotrophic factor does not enter normal mouse brain Neurosci. Lett. 340 2003 239 241
13. A.E. Lang, S. Gill, N.K. Patel, A. Lozano, J.G. Nutt, R. Penn, D.J. Brooks, G. Hotton, E. Moro, P. Heywood, M.A. Brodsky, K. Burchiel, P. Kelly, A. Dalvi, B. Scott, M. Stacy, D. Turner, V.G. Wooten, W.J. Elias, E.R. Laws, V. Dhawan, A.J. Stoessl, J. Matcham, R.J. Coffey, and M. Traub Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease Ann. Neurol. 59 2006 459 466
14. P.A. Lapchak, P.J. Miller, F. Collins, and S. Jiao Glial cell line-derived neurotrophic factor attenuates behavioural deficits and regulates nigrostriatal dopaminergic and peptidergic markers in 6-hydroxydopamine-lesioned adult rats: comparison of intraventricular and intranigral delivery Neuroscience 78 1997 61 72
15. H.J. Lee, B. Engelhardt, J. Lesley, U. Bickel, and W.M. Pardridge Targeting rat anti-mouse transferrin receptor monoclonal antibodies through the blood-brain barrier in the mouse J. Pharmacol. Exp. Ther. 292 2000 1048 1052
16. H.J. Lee, and W.M. Pardridge Pharmacokinetics and delivery of tat and tat-protein conjugates to tissues in vivo Bioconjug. Chem. 12 2001 995 999
17. M. Lundblad, B. Picconi, H. Lindgren, and M.A. Cenci A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function Neurobiol. Dis. 16 2004 110 123
18. W.M. Pardridge Drug and gene delivery to the brain: The vascular route Neuron 36 2002 555 558
19. W.M. Pardridge Biopharmaceutical drug targeting to the brain J. Drug Target. 18 2010 157 167
20. W.M. Pardridge, and R.J. Boado Pharmacokinetics and safety in rhesus monkeys of a monoclonal antibody-GDNF fusion protein for targeted blood-brain barrier delivery Pharm. Res. 26 2009 2227 2236
21. W.M. Pardridge, Y.S. Kang, J.L. Buciak, and J. Yang Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate Pharm. Res. 12 1995 807 816
22. M.F. Salvatore, Y. Ai, B. Fischer, A.M. Zhang, R.C. Grondin, Z. Zhang, G.A. Gerhardt, and D.M. Gash Point source concentration of GDNF may explain failure of phase II clinical trial Exp. Neurol. 202 2006 497 505
23. H. Xiao, Y. Hirata, K. Isobe, and K. Kiuchi Glial cell line-derived neurotrophic factor up-regulates the expression of tyrosine hydroxylase gene in human neuroblastoma cell lines J. Neurochem. 82 2002 801 808
24. C. Yang, D. Hutto, and D.W. Sah Distribution of GDNF family receptor alpha3 and RET in rat and human non-neural tissues J. Mol. Histol. 37 2006 69 77
25. Y. Zhang, F. Calon, C. Zhu, R.J. Boado, and W.M. Pardridge Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism Hum. Gene Ther. 14 2003 1 12
26. Q.H. Zhou, R.J. Boado, J.Z. Lu, E.K. Hui, and W.M. Pardridge Monoclonal antibody-glial-derived neurotrophic factor fusion protein penetrates the blood-brain barrier in the mouse Drug Metab. Dispos. 38 2010 566 572